Company Overview of Celladon Corporation
Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure. The company is also developing membrane-bound form of Stem Cell Factor for the treat...
11988 El Camino Real
San Diego, CA 92130
Founded in 2000
Key Executives for Celladon Corporation
Vice President, General Counsel and Secretary
Total Annual Compensation: $233.8K
Compensation as of Fiscal Year 2014.
Celladon Corporation Key Developments
Celladon Corporation(NasdaqGM:CLDN) dropped from NASDAQ Biotechnology Index
Dec 20 15
Celladon Corporation will be removed from NASDAQ Biotech Index.
Celladon Corporation and Eiger BioPharmaceuticals, Inc. Announce Management Changes
Nov 19 15
The directors and executive officers of Celladon Corporation will resign from their positions with Celladon upon the closing of the proposed merger, and the combined company will be under the leadership of Eiger’s current executive management team with David Cory serving as President and Chief Executive Officer. Following the closing of the proposed merger, the Board of Directors of the combined company is expected to consist of seven members all of whom will be designated by Eiger. The corporate headquarters will be located in the San Francisco Bay Area.
Celladon Corporation Announces Management Changes
Nov 19 15
Celladon Corporation announced that, as part of a further reduction in force implemented in connection with the signing of the merger agreement, Paul Cleveland, President and Chief Executive Officer, is leaving the company effective November 19, 2015 to pursue other industry opportunities. Fredrik Wiklund, Celladon’s Vice President of Corporate Development and Investor Relations has been named Celladon’s President and Chief Executive Officer effective the same date.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 18, 2015
Most Searched Private Companies
Sponsored Financial Commentaries